In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.

Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.

An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.

The goal is an inexpensive point-of-care test that quickly determines an individual’s best treatment options.

Tivicay (dolutegravir) is a next-generation integrase inhibitor.

Most of such drug resistance seen is to older drugs.

In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.

The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.

However, two similar cases have been reported in Australia.

U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.